Ann: NTI Receives HREC Approval for Rett Syndrome Clinical Trial, page-6

are we back to this now?



we know what it is....the market knows what it is
we need positive ongoing reporting of this:


example:
an interim DSMB ( or bi- quarterly ) would drive value if the outcomes are being successful
it would draw market attention and volume which drives retail liquidity ....

not more HRECs on other indications .....they can occur in parallel but not as additional clinical investigations

I could be completely wrong but I'm not feeling comfortable with the progress or strategic direction of the last 6 months - these guys should be driving value in the current tightening macro - NTI 164 for autism is a total gamechanger globally ....drive it toward volume and liquidity or the company assets will realise no advantage

as I said - i could be completely wrong